Table 4.
Uni- and multivariate analysis for factors associated with DMFS
| Patient characteristics | n | Univariate | Multivariate | ||
|---|---|---|---|---|---|
| Median DMFS | p-value | HR (95% CI) | p-value | ||
| ISUP score | 0.929 | 1.45 (0.56–3.71) | 0.442 | ||
| ≤ 3 | 39 | NR | |||
| ≥ 4 | 61 | NR | |||
| Initial tumor stage | 0.456 | 1.02 (0.26–4.08) | 0.978 | ||
| ≤ T2 | 21 | NR | |||
| ≥ T3 | 79 | NR | |||
| Initial nodal stage | 0.685 | 0.75 (0.32–1.73) | 0.491 | ||
| N0 | 54 | NR | |||
| N1 | 42 | NR | |||
| Number of lymph node metastases | 0.447 | 1.21 (0.72–2.02) | 0.469 | ||
| 1 | 35 | NR | |||
| 2 | 23 | 54.8 | |||
| ≥ 3 | 42 | 53.9 | |||
| Lymph node localization | 0.276 | 1.39 (0.49–3.93) | 0.534 | ||
| Pelvic | 83 | NR | |||
| Paraaortic (± pelvic) | 17 | 32.2 | |||
| Concomitant ADT | 0.037 | 0.25 (0.07–0.89) | 0.033 | ||
| Present | 83 | NR | |||
| Absent | 17 | 12.4 | |||
| ADT duration | 0.342 | 0.84 (0.35–2.03) | 0.693 | ||
| ≤ 12 months | 40 | NR | |||
| > 12 months | 39 | NR | |||
| PSA persistence vs. PSA recurrence | 0.152 | 2.26 (0.51–9.90) | 0.281 | ||
| PSA persistence | 76 | 61.6 | |||
| PSA recurrence | 22 | NR | |||
| PSA before sRT | 0.012 | 2.56 (1.01–6.46) | 0.047 | ||
| < 1 ng/ml | 42 | NR | |||
| ≥ 1 ng/ml | 58 | 38.7 | |||
| Local recurrence | 0.285 | 0.90 (0.37–2.19) | 0.814 | ||
| No local recurrence | 71 | NR | |||
| Local recurrence | 29 | 45.4 | |||
Abbreviations: ADT androgen deprivation therapy; CI confidence interval; HR hazard ratio; ISUP International Society of Urological Pathology; NR not reached; PSA prostate-specific antigen; sRT salvage radiotherapy
Bold values denote statistical significance at the p < 0.05 level